Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC By Ogkologos - June 25, 2025 545 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer EMA Recommends Extension of Indications for Selpercatinib MOST POPULAR Acing it: The ambitious early career researchers driving progress in cancer... January 21, 2022 Forging Military Partnerships to Empower the Cancer Research Enterprise March 27, 2018 The rise of the ‘long-waiter’ – why cancer waiting times are... November 10, 2022 Comprehensive Genomic Profiling with Molecularly-Guided Therapy Results in Longer PFS Compared... August 26, 2024 Load more HOT NEWS ASCO20 Virtual Research Round Up Podcast: Breast Cancer, Sarcoma, and Supportive... Picking out the patterns: How scientists are finding cancer’s signatures in... Doxorubicin and Trabectedin Combination Improves Survival Among Patients with Metastatic or... Study in India Could Make Immunotherapy More Affordable Worldwide
